A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
A phase 3 trial of Daratumumab, Dexamethasone and Pomalidomide in multiple myeloma, run by Biocad, now recruiting.
Overview
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) is a phase 3 interventional study registered as NCT07742215 by Biocad, with 390 participants planned, started 2026-06-15 and due to reach its primary completion in 2028-07. Interventions recorded: BCD-248 + daratumumab and Daratumumab + pomalidomide + dexamethasone.
Similar pages
not linked directly; found by shared links- TrialAn Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Shares Biocad, Multiple myeloma and the tag pipeline.
- TrialBCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Shares Biocad and the tag pipeline.
- TrialClinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer
Shares Biocad and the tag pipeline.
- TreatmentBCD-100
Shares Biocad and the tag pipeline.
- TrialIsatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TreatmentBCD-217
Shares Biocad and the tag pipeline.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.